Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) and Golden Dragon (OTCMKTS:CPMD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Insider and Institutional Ownership
59.2% of Ocular Therapeutix shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 1.3% of Golden Dragon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Ocular Therapeutix and Golden Dragon”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ocular Therapeutix | $51.95 million | 35.19 | -$265.94 million | ($1.46) | -5.72 |
| Golden Dragon | $1.36 million | 1.29 | -$11.13 million | ($0.01) | -0.26 |
Golden Dragon has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Golden Dragon, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Ocular Therapeutix has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Golden Dragon has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.
Profitability
This table compares Ocular Therapeutix and Golden Dragon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ocular Therapeutix | -558.24% | -64.28% | -48.15% |
| Golden Dragon | -654.02% | N/A | -118.00% |
Analyst Ratings
This is a summary of current recommendations and price targets for Ocular Therapeutix and Golden Dragon, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocular Therapeutix | 1 | 1 | 12 | 0 | 2.79 |
| Golden Dragon | 0 | 0 | 0 | 0 | 0.00 |
Ocular Therapeutix presently has a consensus target price of $23.78, suggesting a potential upside of 184.76%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than Golden Dragon.
Summary
Ocular Therapeutix beats Golden Dragon on 9 of the 14 factors compared between the two stocks.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
About Golden Dragon
CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
